Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.

Beard CM, Kokmen E, O'Brien PC, Kurland LT. Are patients with Alzheimer's disease surviving longer in recent years? Neurology 1994;44:1869-1871.

Beier, MT. Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease. The Consultant Pharmacist 2001;(Suppl C):7-13.

Blass JP, Ko L, Wisniewski HM. Pathology of Alzheimer's disease. Psychiatr Clin N Am 1991;14:397.

Bowen JD, Larson EB. Drug-induced cognitive impairment: Defining the problem and finding solutions. Drugs & Aging 1993;3:349-357.

Brandt J, Rich JB. Memory disorders in the dementias. In Handbook of Memory Disorders. Baddeley AD, Wilson VA, Watts FN (eds). (John Wiley & Sons Ltd, 1995).

Buckwalter KC, Maas M, Reed D. Assessing family and staff caregiver outcomes in Alzheimer's disease research. Alzheimer Dis Assoc Disord. 1997;11(suppl 6):105-116.

Costa PT Jr, Williams TF, Somerfield M, et al. Recognition and Initial Assessment of Alzheimer’s Disease and Related Dementias. Clinical Practice Guideline No. 19. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 97-0702. November 1996.

Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research in Alzheimer's disease. Clin Pharmacol Ther. 1995;58:228-236.

Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate Alzheimer’s disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.

Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.

Biol Psychiatry. 2001 Feb 1;49(3):289-99.

Cummings JL. Changes in neuropsychiatric symptoms as outcomes measures in clinical trials with cholinergic therapies for Alzheimer disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 4):S1-S9.

Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4-15.

Cummings JL, Mega M, Rosenberg-Thompson S, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.

Cummings JL, Vinters HV, Cole GM et al. Alzhiemer’s disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51(suppl 1):S2-S17.

Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33.

Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subc9ommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.

Duncan BA and Siegal AP. Early diagnosis and management of Alzheimer’s disease. J Clin Psychiatry 1998;59 (suppl 9):15-21.

Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. Neurology. 1998;51(Suppl 1):553-560.

Emilien G, Beyreuther K, Masters CL, et al. Prospects for pharmacological intervention in Alzheimer disease. Arch Neur. 2000;57:454–459.

Evans DA, Funkenstein HH, Abert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA. 1989;262:2551-2556.

Farlow MR and Evans RM. Pharmacologic treatment of cognition in Alzheimer’s dementia. Neurology 1998;51 (Suppl 1):S36-S44.

Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease:

implications for switching to galantamine. Clin Ther. 2001;23 Suppl A:A13-24.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Neurology. 2001 Aug 28;57(4):613-20.

Ferris SH. Switching previous therapies for Alzheimer's disease to galantamine. Clin Ther. 2001;23 Suppl A:A3-7.

Fleming KC, Adams AC, Petersen RC. Dementia: Diagnosis and evaluation. Mayo Clin Proc 1995;70:1093-1107.

Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-147.

Giacobini E. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications [review]. Neurochem Int. 1998;32:413-419.

Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry. 2000;15:242-247.

Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet 1992;340:645.

Hebert LE, Sherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer’s disease in a community population. JAMA. 1995;273:1354-1359.

Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ. 1998;159:457-465.

Jann MW. Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy. 2000;20:1-12.

Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44:1078-1081.

Kaufer DI, Catt KE, Lopez OL, et al. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology. 1998;51:1512.

Leon J, Cheng CK, Neumann PJ. Alzheimer’s disease care: costs and potential savings. Health Affairs. 1998;17:206-216.

Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-1332.

Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord. 2000;11(suppl S1):11-18.

Maelicke A. Pharmacokinetic rationale for switching from donepezil to galantamine.

Clin Ther. 2001;23 Suppl A:A8-12.

Morris JC, Farlow MR, Ferris SH, Kurz AF, Maelicke A, Rasmusen L, Wilkinson

D, Yan B. Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers. Clin Ther. 2001;23 Suppl A:A31-9.

McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Ger Psychiatry. 2000;15:387-392.

Mega MS, Masterson DM, O’Connor SM. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer’s Disease. Arch Neurol. 1999;56:1388-1393.

Masur DM, Sliwinski M, Lipton RB et al. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994;44:1427-1432.

McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-943.

Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

Neurology. 2001 Aug 14;57(3):481-8.

Morris JC, Rubin EH. Clinical diagnosis and course of Alzheimer's disease. Psychiatr Clin N Am 1991:14:223.

National Institutes of Health. Differential diagnosis of dementing diseases. Consensus Conference. JAMA 1987;258:3411-3416.

Nordberg A, Svensson AL . Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Safety. 1998;19:465-480.

O'Donnell B, Drachman D, Barnes H, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45-52.

Pitchumoni SS and Doraiswamy PM. Current status of antioxidant therapy for Alzheimer’s disease. J Am Geriatr Soc 1998;46:1566-1672.

Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54: 2261-2268.

Rasmusen L, Yan B, Robillard A, Dunbar F. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther. 2001;23 Suppl A:A25-30.

Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136-145.

Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol. 1998;8:67-75.

Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ. 1999;318:633-640.

Rustead JM, Newhouse PA, Levin ED, et al. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease. Behav Brain Res. 2000;113:121-129.

Richards SS and Hendrie HC. Diagnosis, management, and treatment of Alzheimer disease: A guide for the internist. Arch Int Med 1999;159:789-798.

Shadlen MF, Larson EB. What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Postgrad Med. 1999;105:109-118.

Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr. 1998; 10:229-238.

Shepherd G, Klein-Schwartz W, Edwards R . Donepezil overdose: a tenfold dosing error. Ann Pharmacother. 1999;33:812-815.

Small GW. The pathogenesis of Alzheimer’s disease. J Clin Psych 1998;59 (suppl 9):7-14.

Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.

Stahl SM. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1.

Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147:1049-1051.

Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.

Vatasery GT. Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics 1998;53 (Suppl 1):S25-S27.

Winblad B and Poritis N. Memantine in severe dementia: Results of the M-BEST Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriat Psychiatry 1999:14:135-146.

Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Sep;16(9):852-7.